Breaking News

Premier Research Adds Clinicians

March 19, 2013

Expands pediatrics and rare disease clinical divisions

Premier Research has added four clinicians to key leadership roles in its pediatric and rare disease clinical research divisions. Dr. Susan P. Tansey, MBCHB, MRCP, CCST, has been appointed medical director of pediatrics. Her medical specialty areas include vaccines, cardiovascular, oncology, neonatology and pediatric medicine. She has considerable experience in pediatric clinical research and trial design. Dr. Tansey joins the company from TMC Pharma Services, where she was director of medical services. She previously had held research positions at Pfizer, Wyeth, and Servier R&D.
Dr. Ilze Balode, a neonatologist and pediatrician, has been named senior project manager at Premier Research Europe based in Latvia. She has global experience in the CRO and pharmaceutical industries with expertise in infectious diseases, pediatric dermatology, central nervous system, oncology, endocrinology, genitourinary, and respiratory conditions. Dr. Balode joins the company from ICON Clinical Research, where she was a project manager.
Dr. Alison Sampson has been named project director at Premier Research Europe, based in the UK. Dr. Sampson is an experienced global clinical trials veteran with expertise in Phase I, II, and III oncology, medical devices, and rare diseases, particularly in pediatrics and neonates. Previously she was project director for oncology at INC Research, UK.
Mary Kay Seeland has been named director of clinical planning and study start-up based in the U.S. Ms. Seeland previously had managed clinical operations at Pharmaceutical Research Associates International (PRA). Prior to that, she held positions in clinical management and regulatory affairs at Amicus Therapeutics and Johnson & Johnson.

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research